Protagenic Therapeutics, Inc. (PKTX)
OTCQB OTCQB Primary Summary
PKTX Chart
Protagenic Therapeutics, Inc. Dividends
Protagenic Therapeutics, Inc. Earnings
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Mar 2025 Date | | - Cons. EPS | - EPS |
| 1 Nov 2024 Date | | - Cons. EPS | - EPS |
| 18 Oct 2024 Date | | - Cons. EPS | - EPS |
| 16 Oct 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Mar 2025 Date | | - Cons. EPS | - EPS |
| 1 Nov 2024 Date | | - Cons. EPS | - EPS |
| 18 Oct 2024 Date | | - Cons. EPS | - EPS |
| 16 Oct 2024 Date | | - Cons. EPS | - EPS |
Protagenic Therapeutics, Inc. (PKTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Protagenic Therapeutics, Inc. ever had a stock split?
Protagenic Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Clarence Edward Smith CEO | OTCQB Exchange | US7437221002 ISIN |
| US Country | - Employees | - Last Dividend | 29 Apr 2002 Last Split | - IPO Date |
Overview
ProtoKinetix, Incorporated is a pioneering bio-technology company engaged in the research and development stage, primarily focused on the exploration of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). These compounds hold potential for significant scientific and medical advancements. Originally established as RJV Network, Inc., the firm underwent a rebranding to ProtoKinetix, Incorporated in July 2003, marking a pivotal redirection towards its current innovative focus. Since its incorporation in 1999, the company has been dedicated to harnessing the potential of AFGPs for a range of healthcare applications, working out of its headquarters in Dalton, Ohio. Additionally, it has engaged in valuable collaborative research endeavors with esteemed institutions like the University of British Columbia to further its mission.
Products and Services
- Ophthalmology Applications
ProtoKinetix's AFGPs show promise for treating and managing various eye diseases and conditions. These glycoproteins could potentially protect cells in the eye from damage caused by freezing temperatures or decrease age-related degeneration, thereby improving eye health and vision.
- Dermatology Uses
In the field of dermatology, the company's glycoproteins have applications in skin health, including the protection of skin cells from environmental stresses and the aging process. Their research aims at developing treatments that could rejuvenate skin and repair damage caused by various factors, potentially reducing wrinkles and age spots.
- Transplant Solutions
One of the groundbreaking applications of AFGPs is in the area of organ and tissue transplants. These glycoproteins could significantly enhance the viability of transplants by reducing cellular damage during the freezing and thawing processes, thus improving the success rates of such medical procedures and saving lives.
- Biomanufacturing Processes
ProtoKinetix's research into AFGPs contributes to advancements in biomanufacturing, particularly in the preservation of biological materials. By incorporating these glycoproteins into biomanufacturing processes, it is possible to enhance the stability and viability of bio-products, making the company a valuable partner in the biotech manufacturing sector.
Contact Information
